Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
Michael L. West(Dalhousie University), Raphael Schiffmann(Texas Christian University), Bruce A. Barshop(University of California San Diego), Atul Mehta(University College London), Robert D. Steiner(University of Wisconsin–Madison), William J. Rhead(Children's Hospital of Wisconsin), Kathy Nicholls(Melbourne Health), Robert Mensah(Massachusetts General Hospital), Markus Ries(Heidelberg University), Michael Beck(Eastern Illinois University), Joe T.R. Clarke(Dalhousie University)
Cited by 162
Related Papers
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
|Nephrology Dialysis Transplantation|2009|366